Courtney Marshall
Psychiatric/Mental Health · Crofton, MDNPI 1871512350
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 84 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $552, 3.9 times the $142 reported in 2021.
Across 84 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$220
- AbbVie$193
- Alkermes, Inc.$151
- Otsuka America Pharmaceutical, Inc.$141
- Tris Pharma Inc$132
- Axsome Therapeutics, Inc.$106
- plus $669 from 15 others
What the payments were for
- Food & beverage$1,612100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $220 |
| AbbVie | 10 | $193 |
| Alkermes, Inc. | 8 | $151 |
| Otsuka America Pharmaceutical, Inc. | 2 | $141 |
| Tris Pharma Inc | 7 | $132 |
| Axsome Therapeutics, Inc. | 5 | $106 |
| Lundbeck LLC | 5 | $86 |
| Corium, LLC | 6 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $71 |
| Teva Pharmaceuticals USA, Inc. | 3 | $68 |
| Supernus Pharmaceuticals, Inc. | 4 | $62 |
| Idorsia Pharmaceuticals US Inc | 3 | $53 |
| Abbott | 1 | $43 |
| Bausch Health US, LLC | 2 | $41 |
| Merck | 2 | $36 |
| Sunovion Pharmaceuticals Inc. | 3 | $35 |
| Vanda Pharmaceuticals Inc. | 2 | $31 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| GSK | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| TMS Neurohealth Centers Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$121
How this compares
$1,612 in reported general payments places this provider in the 80th percentile of 1,461 psychiatric/mental health providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 70 | $5,203 |
| Dextroamphetamine Sulfate | 11 | $4,407 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 34 | $3,345 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 56 | $2,596 |
| Trazodone Hcl | 61 | $1,759 |
| Duloxetine Hcl | 54 | $1,523 |
| Olanzapine | 20 | $1,460 |
| Bupropion XlBupropion Hcl | 41 | $1,355 |
| Amitriptyline Hcl | 24 | $1,089 |
| Quetiapine Fumarate | 33 | $914 |
| Lamotrigine | 65 | $876 |
| Atomoxetine Hcl | 16 | $868 |
| Buspirone Hcl | 23 | $689 |
| Clonazepam | 52 | $628 |
| Alprazolam | 55 | $610 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Crofton
- Gedeon LongtchiCrofton$6K
- Edith LinvilleCrofton$6K
- Hara OyedejiOwings Mills$780K
- Ilya RozenbergGlen Burnie$572K
- Michelle WilliamsColumbia$158K
- Kristin ClemensGaithersburg$36K
- Antonio HeroldHavre de Grace$23K
- Paul KlaverweidenFruitland$17K
- Margaret WebbAberdeen$16K
- Susan KrausTowson$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.